Kerstin Heurling, PET Imaging Director at Antaros Medical, has contributed to generating new insights on the effect of cerebral blood flow on amyloid quantification with PET imaging presented in the recent paper: Simulating the effect of cerebral blood flow changes on regional quantification of [18F]flutemetamol and [18F]florbetaben studies.
One hallmark of Alzheimer’s disease is the accumulation of amyloid-beta the brain. This accumulation can be visualized and quantified with positron emission tomography (PET). Changes in cerebral blood flow can affect the accuracy of the PET amyloid load quantification and needs to be considered, especially when measuring disease progression or treatment response in clinical trials.